PD-1 and chemotherapy
Phase 2Small molecule
PD-1 and chemotherapy is one of 7 small molecule programs targeting Biliary Tract Cancer (BTC). It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
8 competitors in Biliary Tract Cancer (BTC)
#DrugCompanyPhaseTrials
1Zaniducla
Jazz PharmaceuticalsPhase 3
Lytgobi
Taiho Oncology, Inc.Phase 3
Tibsovo
SServier
Phase 3
Gemzar
Johnson & JohnsonPhase 2
Iparomlimab and Tuvonralimab
Qilu Pharmaceutical Co., Ltd.Phase 2
PD-1 Inhibitors
BBioNTech US Inc.
Phase 2
PD-1 and chemotherapy
TTongji University
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Driver Mutation1 trial
Biliary Tract Cancer (BTC)1 trial
Safety and Effectiveness of Sequential Cryoablation With Rilafup α and Chemotherapy as First-line Treatment for Intrahepatic Cholangiocarcinoma and Gallbladder Cancer: a Multicenter, Prospective, Single-arm, Phase II Clinical Study
Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT07726446·30 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PD-1 and chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- TTongji University